These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23122783)

  • 41. Innovative therapy for patients with brain metastases: oral treatments.
    Kopf B; De Giorgi U; Zago S; Carminati O; Rosti G; Marangolo M
    J Chemother; 2004 Nov; 16 Suppl 5():94-7. PubMed ID: 15675490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypertriglyceridemia in patients with metastatic breast cancer and treatment with capecitabine.
    Geva S; Lazarev I; Geffen DB; Ariad S
    J Chemother; 2013 Jun; 25(3):176-80. PubMed ID: 23783143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.
    Rogers LR; Remer SE; Tejwani S
    Neuro Oncol; 2004 Jan; 6(1):63-4. PubMed ID: 14769142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
    Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
    Nakamura Y; Aono T; Nomura M; Iwase K; Tanaka Y
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2165-8. PubMed ID: 21084819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.
    Mukesh M; Murray P
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):382-3. PubMed ID: 18407475
    [No Abstract]   [Full Text] [Related]  

  • 50. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
    Welslau M; Diéras V; Sohn JH; Hurvitz SA; Lalla D; Fang L; Althaus B; Guardino E; Miles D
    Cancer; 2014 Mar; 120(5):642-51. PubMed ID: 24222194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
    Bianchi GV; Duca M; Sica L; Mariani G
    Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ten years of HER2-directed therapy: still questions after all these years.
    Krop IE; Winer EP
    Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
    [No Abstract]   [Full Text] [Related]  

  • 53. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
    Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combination therapy herceptin+xeloda].
    Schaller G
    Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
    [No Abstract]   [Full Text] [Related]  

  • 55. Lapatinib plus capecitabine in breast cancer.
    Sonpavde G
    N Engl J Med; 2007 Apr; 356(14):1471; author reply 1471-2. PubMed ID: 17409332
    [No Abstract]   [Full Text] [Related]  

  • 56. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
    Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
    Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Capecitabine therapy of central nervous system metastases from breast cancer.
    Ekenel M; Hormigo AM; Peak S; Deangelis LM; Abrey LE
    J Neurooncol; 2007 Nov; 85(2):223-7. PubMed ID: 17611719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
    Truchuelo M; Vano-Galvan S; Pérez B; Muñoz-Zato E; Jaén P
    Dermatol Online J; 2009 Mar; 15(3):7. PubMed ID: 19379651
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How addition of capecitabine might be more beneficial in the neoadjuvant treatment of breast cancer.
    Ararat E; Sahin I; Altundag K
    J BUON; 2011; 16(2):377. PubMed ID: 21766519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.